Lu AF28996 in Participants With Parkinson's Disease (PD)
Completed · Phase 1 · NCT04291859
Conditions: Parkinson Disease
At a glance
- Research payments reported, 2025
- $296,334
- U.S. investigators named
- 8
- Sites paid
- 8
- Planned or actual enrollment
- 57
About the trial
- Sponsor
- H. Lundbeck A/S
- Tested
- Lu AF28996 (drug)
- Dates
- Started 2020-02-26; completion 2026-02-12
- Results posted
- Not yet
The purpose of this study is to investigate the safety of Lu AF28996, how well it is tolerated and what the body does to the drug in participants with Parkinson's disease.
From ClinicalTrials.gov, last updated 2026-03-06. Full record, eligibility and contacts (opens in a new tab)
Industry funding
H. Lundbeck A S reported $296,334 in research payments for this study in 2025 (48 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Omid Omidvar, M.D. Neurology · Los Alamitos, CA
- Fernando Pagan Neurology · Washington, DC
- Ramon A. Gil, MD Specialist · Port Charlotte, FL
- Beth E. Safirstein Neurology · Hallandale Beach, FL
- Kore K. Liow, MD Neurology · Honolulu, HI
- Aaron L. Ellenbogen, D.O. Neurology · Farmington Hills, MI
- Howard E. Gendelman, MD Infectious Disease · Omaha, NE
- Gene W. Voskuhl, MD Infectious Disease · Sherman, TX
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Hawaii PAcific Neuroscience (hpn) - Honolulu $119,041
- Medstar Georgetown University Hospital, DC $115,704
- University of Nebraska Medical Center $30,649
- Cenexel Collaborative Neuroscience Research LLC Los Alamitos $21,495
- Fortrea Clinical Research Unit - Dallas $6,374
- Velocity Clinical Research Hallandale Beach $2,501
- Quest Research Institute - Farmington Hills $485
- Charlotte Neurological Services (parkinson's Disease Treatment Center of Sw Florida) $85
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.